D

Dignity Health | Comprehensive Blood and Cancer Center

Research site
(Unclaimed)
Location
6501 Truxtun, Avenue, Suite 900, Bakersfield, California, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel
Bevacizumab
Abemaciclib
Gemcitabine
LY2835219
Leucovorin
Nivolumab
Docetaxel
Bortezomib
Irinotecan

Parent organization

This site is a part of Dignity Health

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 78 total trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who c...

Enrolling
Multiple Myeloma
Drug: Ruxolitinib Oral Tablet [Jakafi]
Drug: Methylprednisolone
Locations recently updated

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered...

Enrolling
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Drug: Gemcitabine
Drug: Nab-paclitaxel

The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.

Active, not recruiting
Non Small Cell Lung Cancer
Drug: Erlotinib
Drug: Abemaciclib

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women wit...

Active, not recruiting
Breast Cancer
Drug: Letrozole
Drug: Placebo

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...

Active, not recruiting
Metastatic Adenocarcinoma of the Pancreas
Drug: Leucovorin
Drug: Gemcitabine

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol inv...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Elotuzumab

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Carboplatin
Drug: Datopotamab Deruxtecan

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive an...

Enrolling
Breast Cancer
Biological: Placebo
Biological: GLSI-100

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent...

Enrolling
Solid Tumor
Melanoma Stage IV
Drug: GIM-531
Drug: Anti-PD-1 monoclonal antibody

This is a phase 3 study to compare the efficacy and safety of HBI-8000 or Placebo combined with nivolumab on patients with unresectable or metastatic...

Enrolling
Progressive Brain Metastasis
Unresectable or Metastatic Melanoma
Drug: Placebo in combination with nivolumab
Drug: HBI-8000 in combination with nivolumab

Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC

Active, not recruiting
Non-small Cell Lung Cancer
Biological: Pembrolizumab
Drug: Pemetrexed

Trial sponsors

Lilly logo
O
Bristol-Myers Squibb (BMS) logo
T
Pfizer logo
C
Gilead Sciences logo
Novartis logo
T
Celgene logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems